ChemicalBook >> CAS DataBase List >>VTP50469 fumarate

VTP50469 fumarate

CAS No.
2169919-29-1
Chemical Name:
VTP50469 fumarate
Synonyms
VTP50469 fumarate
CBNumber:
CB58054578
Molecular Formula:
C36H51FN6O8S
Molecular Weight:
746.9
MDL Number:
MOL File:
2169919-29-1.mol
Last updated:2023-05-21 10:59:17

VTP50469 fumarate Properties

storage temp. 4°C, away from moisture and light
solubility DMSO : 220 mg/mL (273.32 mM; Need ultrasonic)

VTP50469 fumarate Chemical Properties,Uses,Production

Biological Activity

VTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 fumarate has potently anti-leukemia activity[1][2]. VTP50469 more potently and rapidly inhibits cell proliferation in a concentration-dependent manner in MLL-r cell lines carrying (MOLM13 (IC50 of 13 nM), THP1 (IC50 of 37 nM), NOMO1 (IC50 of 30 nM), ML2 (IC50 of 16 nM), EOL1 (IC50 of 20 nM), and murine MLL-AF9 cells (IC50 of 15 nM)) and ALL (KOPN8 (IC50 of 15 nM), HB11;19 (IC50 of 36 nM), MV4;11 (IC50 of 17 nM), SEMK2 (IC50 of 27 nM), and RS4;11 (IC50 of 25 nM)) cell lines[1].At early timepoints MLL-r B cell ALL (B-ALL) cell lines, but not MLL-r AML cell lines, underwent apoptosis in response to VTP50469 in a dose-dependent manner. MLL-r AML cell lines underwent dose-dependent differentiation starting at 4-6 days of exposure to VTP50469[1]. VTP50469 displaces Menin from protein complexes and inhibits chromatin occupancy of MLL at select genes. Loss of MLL binding led to changes in gene expression, differentiation, and apoptosis[1]. VTP50469 (15-60 mg/kg; oral administration; twice a day; for 28 days; NSG mice) treatment is highly efficacious across all dosage levels and all treatment groups have a significant survival advantage. Mice dosed at 30 and 60 mg/kg VTP50469 extends survival advantage[1].

References

[1]. Krivtsov AV, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 Dec 9;36(6):660-673.e11. [2]. Andrei V. Krivtsov, et al. Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia. Cancer Resceach. July 2018.Volume 78, Issue 13 Supplement.

VTP50469 fumarate Preparation Products And Raw materials

Raw materials

Preparation Products

VTP50469 fumarate Suppliers

Global( 2)Suppliers
Supplier Tel Email Country ProdList Advantage
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000 marketing@targetmol.com United States 19892 58
RD International Technology Co., Limited 18024082417 market@ubiochem.com China 9180 58

2169919-29-1(VTP50469 fumarate)Related Search:

VTP50469 fumarate 2169919-29-1